| 초록 |
Background: IgA nephropathy is the most common glomerulonephritis. and recurrent IgA nephropathy in the transplanted kidney is common and can lead to graft failure. no guideline for the treatment of recurrence of IgA nephropathy in renal transplants are currently available. we therefore investigated the effects of methylprednisolone pulse therapy in patients with biopsy proven recurrent IgA nephropathy.
Methods: Between 2008 and 2013, 12 renal transplants (6 males, 6 females) with biopsy proven recurrent IgA nephropathy were treated with 500mg intravenous methyl prednisolone every 2 weeks for 6 months to improve or stabilize renal function. the efficacy of MP pulse therapy was analysed by comparing the change of eGFR (ml/min/ 1.73m2) and urine albumin to creatinine ratios(mg/g) before, during, after treatment using paired T-test.
Results: 10 patients completed the planned 6 months of MP pulse therapy. and there were follow up for a median 23 months (range 4-47months) after therapy. median ininitial estimated GFR is 42.83±16.67. 8 of our 10 patients improvement of eGFR after treatment compared with befere treatment (initial eGFR-after eGFR= -7.25±13, t=-1.82, p=0.096). patients with severe tubular atrophy or combined acute cellular rejection were decreased response to MP pulse therapy. all patients with initial urine albumin to creatinine ratio >500 mg/g showed improved(initial albumin to creatinine ratio-after albumin to creatinine ratio=138.9±176.23, t=2.73, p=0.02). MP pulse therapy was generally well tolerated. there are no patients required renal replacement therapy during the follow up periods.
Conclusion: MP 500 mg every 2 weeks for 6months was safe and effective in kidney transplantation patients with recurrent IgA nephropathy. |